BACKGROUND Prostate cancer is the most frequent malignancy in men and predominantly in elderly men. Androgen-deprivation therapy (ADT), either alone or in combination with antiandrogens is recommended treatment for men with metastatic or locally advanced disease. ADT has a number of important adverse effects, most of which are a consequence of drug-induced hypogonadism. One of the most common and clinically significant adverse effects includes osteoporosis and increased risk of fractures. OBJECTIVE This study assesses the screening for the prevention of osteoporosis among53 patients with locally advance prostate cancer. The follow-up for osteoporosis was made after 12 months, 24 months and 36 months. RESULT After 36 months, 10 patients had no changes in bone structure, 20 patients showed signs of osteopenia and 7 patients had osteoporosis. CONCLUSIONS Most men treated with ADT for prostate cancer did not receive osteoporosis screening, prevention or treatment. Further research is needed to identify optimal strategies for screening, prevention, and treatment in this population.
OSTEOPOROSI IN PAZIENTI ANZIANI IN TRATTAMENTO ORMONALE PER CARCINOMA DELLA PROSTATA LOCALMENTE AVANZATO
GAMBARDELLA, Antonio;
2013
Abstract
BACKGROUND Prostate cancer is the most frequent malignancy in men and predominantly in elderly men. Androgen-deprivation therapy (ADT), either alone or in combination with antiandrogens is recommended treatment for men with metastatic or locally advanced disease. ADT has a number of important adverse effects, most of which are a consequence of drug-induced hypogonadism. One of the most common and clinically significant adverse effects includes osteoporosis and increased risk of fractures. OBJECTIVE This study assesses the screening for the prevention of osteoporosis among53 patients with locally advance prostate cancer. The follow-up for osteoporosis was made after 12 months, 24 months and 36 months. RESULT After 36 months, 10 patients had no changes in bone structure, 20 patients showed signs of osteopenia and 7 patients had osteoporosis. CONCLUSIONS Most men treated with ADT for prostate cancer did not receive osteoporosis screening, prevention or treatment. Further research is needed to identify optimal strategies for screening, prevention, and treatment in this population.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
